BibSonomy publications for /user/kanefendt/DrugBibSonomypublrss/user/kanefendt/DrugBibSonomy RSS feed for /user/kanefendt/Drug2012-02-16T12:09:35+01:00- Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalizationhttp://www.bibsonomy.org/bibtex/2143cacfb64ea0a7986d0ab5e71479dba/kanefendtkanefendt2010-02-05T11:28:39+01:00& Angiogenesis Animals Blood Endothelial Factors Growth Humans Inhibitors Laboratories Neoplasms Neovascularization Pathologic Research Vascular Vessels antagonists blood cells drug inhibitors pathology supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Fukumura">D. Fukumura</a>, and <a href="/author/Jain">R. K. Jain</a> </span><em>Microvasc.Res.</em> <em>74(2-3):72-84</em> (<em>2007</em>)
- Sunitinib efficacy against advanced renal cell carcinomahttp://www.bibsonomy.org/bibtex/230fd986fa9ab1ed24fcf59cfe32f7d3c/kanefendtkanefendt2010-02-05T11:28:39+01:00& Administration Adult Aged Agents Antineoplastic Carcinoma Cell Disease Disease-Free Female Follow-Up Humans Indoles Kidney Laboratories Male Method Middle Neoplasm Neoplasms Oral Outcome Progression Pyrroles Rate Renal Research Retrospective Single-Blind Staging States Studies Survival Treatment Tyrosine United administration dosage drug epidemiology methods mortality pathology response therapy <span class="authorEditorList"><a href="/author/Motzer">R. J. Motzer</a>, <a href="/author/Michaelson">M. D. Michaelson</a>, <a href="/author/Rosenberg">J. Rosenberg</a>, <a href="/author/Bukowski">R. M. Bukowski</a>, <a href="/author/Curti">B. D. Curti</a>, <a href="/author/George">D. J. George</a>, <a href="/author/Hudes">G. R. Hudes</a>, <a href="/author/Redman">B. G. Redman</a>, <a href="/author/Margolin">K. A. Margolin</a>, and <a href="/author/Wilding">G. Wilding</a> </span><em>J.Urol.</em> <em>178(5):1883-1887</em> (<em>2007</em>)
- Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study sampleshttp://www.bibsonomy.org/bibtex/20aa419dc3c83957f2e585cc89e1b0de1/kanefendtkanefendt2010-02-05T11:28:39+01:00Animals Binding Biopharmaceutics Chemistry Control Drug Humans Pharmaceutical Pharmacokinetics Preparations Quality Reference Reproducibility Results Solutions Stability Standards analysis deficiency metabolism methods of standards <span class="authorEditorList"><a href="/author/Nowatzke">W. Nowatzke</a>, and <a href="/author/Woolf">E. Woolf</a> </span><em>AAPS.J.</em> <em>9(2):E117-E122</em> (<em>2007</em>)
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibhttp://www.bibsonomy.org/bibtex/2506ad4630500172729537a9ce24caf9c/kanefendtkanefendt2010-02-05T11:28:39+01:00& Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use <span class="authorEditorList"><a href="/author/Chu">T. F. Chu</a>, <a href="/author/Rupnick">M. A. Rupnick</a>, <a href="/author/Kerkela">R. Kerkela</a>, <a href="/author/Dallabrida">S. M. Dallabrida</a>, <a href="/author/Zurakowski">D. Zurakowski</a>, <a href="/author/Nguyen">L. Nguyen</a>, <a href="/author/Woulfe">K. Woulfe</a>, <a href="/author/Pravda">E. Pravda</a>, <a href="/author/Cassiola">F. Cassiola</a>, <a href="/author/Desai">J. Desai</a>, <a href="/author/George">S. George</a>, <a href="/author/Morgan">J. A. Morgan</a>, <a href="/author/Harris">D. M. Harris</a>, <a href="/author/Ismail">N. S. Ismail</a>, <a href="/author/Chen">J. H. Chen</a>, <a href="/author/Schoen">F. J. Schoen</a>, <a href="/author/van den Abbeele">A. D. van den Abbeele</a>, <a href="/author/Demetri">G. D. Demetri</a>, <a href="/author/Force">T. Force</a>, and <a href="/author/Chen">M. H. Chen</a> </span><em>Lancet</em> <em>370(9604):2011-2019</em> (<em>2007</em>)
- The biology of epidermal growth factor receptor and its value as a prognostic/predictive factorhttp://www.bibsonomy.org/bibtex/286090cbc034bdaa48e8da2ccda1fc004/kanefendtkanefendt2010-02-05T11:28:39+01:00Antibodies Biological Epidermal Expression Factor Gene Growth Human Humans Immunohistochemistry Markers Monoclonal Neoplasms Neoplastic Prognosis Receptor Regulation Tyrosine analysis drug effects etiology identify pathology physiology response therapeutic therapy use <span class="authorEditorList"><a href="/author/Tos">A. P. Dei Tos</a> </span><em>Int.J.Biol.Markers</em> <em>22(1 Suppl 4):S3-S9</em> (<em>2007</em>)
- Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinibhttp://www.bibsonomy.org/bibtex/2dae68b0a9f4d1cf86ed190a3ce1823df/kanefendtkanefendt2010-02-05T11:28:39+01:00Angiogenesis Biological Cells Endothelial Growth Humans Indoles Inhibitors Laboratories Markers Neoplasms Neovascularization Pathologic Proteins Pyrroles Research Tumor blood cells diagnosis drug effects metabolism methods pathology pharmacology protein response supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Deprimo">S. E. Deprimo</a>, and <a href="/author/Bello">C. Bello</a> </span><em>Ann.Oncol</em> (<em>2007</em>)
- Molecular and cellular biomarkers for angiogenesis in clinical oncologyhttp://www.bibsonomy.org/bibtex/23b5cf396d03997444d803a9b55701e09/kanefendtkanefendt2010-02-05T11:28:39+01:00Angiogenesis Antigens Biological Cells Endothelial Humans Inhibitors Markers Microcirculation Neoplasms Neovascularization Pathologic Research Tumor blood cells diagnosis drug metabolism pathology pharmacology supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Bertolini">F. Bertolini</a>, <a href="/author/Mancuso">P. Mancuso</a>, <a href="/author/Shaked">Y. Shaked</a>, and <a href="/author/Kerbel">R. S. Kerbel</a> </span><em>Drug Discov.Today</em> <em>12(19-20):806-812</em> (<em>2007</em>)
- Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challengeshttp://www.bibsonomy.org/bibtex/277bee5565bfa32594d200c2c9fedca93/kanefendtkanefendt2010-02-05T11:28:39+01:00& Antibodies Biological Carcinoma Dosage Drug Epidermal Factor Gene Growth Human Humans Immunohistochemistry Inhibitors Kinase Kinases Lung Markers Monoclonal Mutation Neoplasm Neoplasms Non-Small-Cell Phosphoproteins Predictive Protein Protein-Tyrosine Proteins Proto-Oncogene Quinazolines Receptor Resistance Tests Tyrosine Value analysis antagonists c-akt drug effects erbB-2 erbB-3 genetics identify inhibitors of protein response therapeutic therapy use <span class="authorEditorList"><a href="/author/Cappuzzo">F. Cappuzzo</a>, <a href="/author/Toschi">L. Toschi</a>, <a href="/author/Finocchiaro">G. Finocchiaro</a>, <a href="/author/Ligorio">C. Ligorio</a>, and <a href="/author/Santoro">A. Santoro</a> </span><em>Int.J.Biol.Markers</em> <em>22(1 Suppl 4):S10-S23</em> (<em>2007</em>)
- Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinibhttp://www.bibsonomy.org/bibtex/2beabba54bd2d560c3e6e69f70f2777bd/kanefendtkanefendt2010-02-05T11:28:39+01:00& Aged Agents Angiogenesis Antineoplastic Carcinoma Cardiomyopathies Cell Dysfunction Echocardiography Female Humans Illness Index Indoles Inhibitors Kidney Kinase Kinases Left Neoplasms Protein-Tyrosine Pyrroles Renal Severity Tyrosine Ventricular adverse antagonists chemically contraindications drug effects induced inhibitors of therapy <span class="authorEditorList"><a href="/author/Chorianopoulos">E. Chorianopoulos</a>, <a href="/author/Jager">D. Jager</a>, <a href="/author/Katus">H. A. Katus</a>, and <a href="/author/Frey">N. Frey</a> </span><em>Clin.Res.Cardiol.</em> <em>96(11):829-830</em> (<em>2007</em>)
- Appropriate calibration curve fitting in ligand binding assayshttp://www.bibsonomy.org/bibtex/2bc2ca7992c0575aea1a335cb36445dc3/kanefendtkanefendt2010-02-05T11:28:39+01:00& Algorithms Analytical Binding Calibration Chemistry Dose-Response Drug Ligands Models Pharmaceutical Pharmacokinetics Preparations Protein RANGE Relationship Reproducibility Research Results Sensitivity Specificity Statistical analysis and data metabolism methods numerical of response statistics <span class="authorEditorList"><a href="/author/Findlay">J. W. Findlay</a>, and <a href="/author/Dillard">R. F. Dillard</a> </span><em>AAPS.J.</em> <em>9(2):E260-E267</em> (<em>2007</em>)
- Angiogenesis: an organizing principle for drug discovery?http://www.bibsonomy.org/bibtex/224ae23315709946658083795ddc2c4f5/kanefendtkanefendt2010-02-05T11:28:39+01:00Agents Angiogenesis Animals Antineoplastic Blood Endothelium Humans Inhibitors Neoplasms Neovascularization Pathologic Physiologic Platelets RANGE Research drug effects genetics pathology pharmacology physiology therapeutic therapy use <span class="authorEditorList"><a href="/author/Folkman">J. Folkman</a> </span><em>Nat.Rev.Drug Discov.</em> <em>6(4):273-286</em> (<em>2007</em>)
- Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionhttp://www.bibsonomy.org/bibtex/2602435fc1730c5168f565863b795701d/kanefendtkanefendt2010-02-05T11:28:39+01:00& Adaptor Antibodies Benzenesulfonates Biological Delivery Diseases Drug Enzyme Heart Human Humans Indoles Inhibitors Kinase Kinases Models Monoclonal Mutation Neoplasms Protein Protein-Tyrosine Proteins Proto-Oncogene Pyridines Pyrroles Quinazolines Research Signal Systems Transducing Tyrosine adverse antagonists c-abl cells chemically development drug effects growth induced inhibitors physiology protein response therapy toxicity <span class="authorEditorList"><a href="/author/Force">T. Force</a>, <a href="/author/Krause">D. S. Krause</a>, and <a href="/author/van Etten">R. A. van Etten</a> </span><em>Nat.Rev.Cancer</em> <em>7(5):332-344</em> (<em>2007</em>)
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyhttp://www.bibsonomy.org/bibtex/2ef0f98aaa58251a4ab8b2c0be419ef9e/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity <span class="authorEditorList"><a href="/author/Ebos">J. M. Ebos</a>, <a href="/author/Lee">C. R. Lee</a>, <a href="/author/Christensen">J. G. Christensen</a>, <a href="/author/Mutsaers">A. J. Mutsaers</a>, and <a href="/author/Kerbel">R. S. Kerbel</a> </span><em>Proc.Natl.Acad.Sci.U.S.A</em> <em>104(43):17069-17074</em> (<em>2007</em>)
- Molecular basis for sunitinib efficacy and future clinical developmenthttp://www.bibsonomy.org/bibtex/253e1171b8a15a9f6bacf8979fae3a8bb/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Angiogenesis Animals Carcinoma Clinical Design Drug Endothelial Factor France Growth Humans Indoles Inhibitors Kinase Kinases Neoplasm Neoplasms Protein-Tyrosine Pyrroles Receptors Resistance Topic Trials Tyrosine Vascular adverse antagonists as biosynthesis blood drug effects enzymology inhibitors metabolism pharmacology response supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Faivre">S. Faivre</a>, <a href="/author/Demetri">G. Demetri</a>, <a href="/author/Sargent">W. Sargent</a>, and <a href="/author/Raymond">E. Raymond</a> </span><em>Nat.Rev.Drug Discov.</em> <em>6(9):734-745</em> (<em>2007</em>)
- Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implicationshttp://www.bibsonomy.org/bibtex/216cb496208ca695d0d314b31867b1929/kanefendtkanefendt2010-02-05T11:28:39+01:00& Angiogenesis Capillaries Human Humans Inhibitors Neoplasms Neovascularization Pathologic Research blood control drug metabolism pathology pharmacology prevention supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Harper">J. Harper</a>, and <a href="/author/Moses">M. A. Moses</a> </span><em>EXS</em> (<em>2006</em>)
- Fit-for-purpose method development and validation for successful biomarker measurementhttp://www.bibsonomy.org/bibtex/2514f8edfda6889057d6f46b8895ede87/kanefendtkanefendt2010-02-05T11:28:39+01:00Approval Biological Calibration Chemistry Control Data Design Drug Interpretation Markers Models Quality Reproducibility Research Results Statistical Terminology Topic analysis as of <span class="authorEditorList"><a href="/author/Lee">J. W. Lee</a>, <a href="/author/Devanarayan">V. Devanarayan</a>, <a href="/author/Barrett">Y. C. Barrett</a>, <a href="/author/Weiner">R. Weiner</a>, <a href="/author/Allinson">J. Allinson</a>, <a href="/author/Fountain">S. Fountain</a>, <a href="/author/Keller">S. Keller</a>, <a href="/author/Weinryb">I. Weinryb</a>, <a href="/author/Green">M. Green</a>, <a href="/author/Duan">L. Duan</a>, <a href="/author/Rogers">J. A. Rogers</a>, <a href="/author/Millham">R. Millham</a>, <a href="/author/O'Brien">P. J. O'Brien</a>, <a href="/author/Sailstad">J. Sailstad</a>, <a href="/author/Khan">M. Khan</a>, <a href="/author/Ray">C. Ray</a>, and <a href="/author/Wagner">J. A. Wagner</a> </span><em>Pharm.Res.</em> <em>23(2):312-328</em> (<em>2006</em>)